The present disclosure relates to terahertz (THz) time domain spectroscopy (TDS), and in particular, to the use of THz-TDS in characterizing tissue samples.
Comprehensive tumor characterization requires multiplexed
immunohistochemistry assays that are expensive and time-consuming given the large number of molecular targets needed to identify and validate each tumor property. There is a crucial need for new technologies, such as terahertz time-domain spectroscopy (THz-TDS), which can provide cost effective image-based techniques for probing and identifying the complex tumor microenvironment. Hence, THz time-domain spectroscopy can be applied to probe tissue samples. The THz-TDS technique is a label-free, noninvasive, and nonionizing tool for biomedical imaging, especially in tumor prognosis. THz radiation lacks the energy to break chemical bonds or ionize molecules/atoms in studied tissues, making it harmless to living organisms, in contrast to much higher energy photons such as ultraviolet light or, especially, X-rays. THz-TDS provides submillimeter spatial resolution and molecular fingerprinting by providing both the frequency and time-domain information and could be capable of detecting pancreatic cancers.
However, despite extensive research using on the THz-TDS technique, there is a lack of standardized THz imaging markers to map out the tissue properties. Presently, there are mainly two approaches to report the difference between the tumor and normal tissues; the first is to map an image of time-or frequency-domain signal amplitudes measured at corresponding locations, i.e., the maximum amplitude of the signal from the tumor sample, normalized with respect to a reference (either an empty setup or a healthy control) and the second is to report a difference in the tissue's optical parameters like the refractive index n and/or the absorption coefficient α in the THz frequency region.
Pancreatic ductal adenocarcinoma (PDAC) is one of the significant reasons for cancer-related death in the United States due to a lack of timely prognosis and the poor efficacy of the standard treatment protocol. Immunotherapy-based neoadjuvant therapy, such as stereotactic body radiotherapy (SBRT), has shown promising results compared to conventional radiotherapy in strengthening the antitumor response in PDAC. To probe and quantify the antitumor response with SBRT, the present disclosure studies the tumor microenvironment using terahertz time-domain spectroscopy (THz-TDS). Since the tumor's complex microenvironment plays a key role in disease progression and treatment supervision, THz-TDS can be a revolutionary tool to help in treatment planning by probing the changes in the tissue microenvironment. In an experimental embodiment, this paper presents THz-TDS of paraffin-embedded PDAC samples utilizing a clinically relevant mouse model. The present disclosure provides a time-domain approximation method based on maximum a posteriori probability (MAP) estimation to extract terahertz parameters, namely, the refractive index and the absorption coefficient, from THz-TDS. Unlike the standard frequency-domain (FD) analysis, the parameters extracted from MAP construct better-conserved tissue parameters estimates, since the
FD optimization often incorporates errors due to numerical instabilities during phase unwrapping, especially when propagating in lossy media. The THz-range index of refraction extracted from MAP and absorption coefficient parameters report a statistically significant distinction between PDAC tissue regions and their healthy equivalents. The coefficient of variation of the refractive index extracted by MAP is one order of magnitude lower compared to the one extracted from FD analysis. The index of refraction and absorption coefficient extracted from the MAP are suggested as the best imaging markers to reconstruct THz images of biological tissues to reflect their physical properties accurately and reproducibly. The obtained THz scans were validated using standard histopathology.
The present disclosure provides a method and technique used for the detection of various tumor microenvironments, such as tumor, edema, or fibrosis, using pulsed terahertz time-domain spectroscopy (TH-TDS) to obtain high-resolution images (e.g., 2-dimensional (2D) images). This is a computational method based on a mathematical model for detecting the tissue microenvironment by extracting optical (within THz bandwidth) imaging markers, namely the refractive index n and the absorption coefficient α, directly from the raw THz-TDS signals. Since the physical characteristics of constituents of a particular type of tissue region can be best reflected by the above n and α markers, using them to create 2D imaging maps can give an unbiased and reproducible way of detecting and visualizing various tissue regions. In previous techniques, the raw THz-TDS signals are converted first into the frequency domain, and then the corresponding electromagnetic wave propagation equations are solved in order to obtain n and α spectra of the tissue. The real part of n is derived by unwrapping the phase of these frequency-domain THz spectra, which introduces numerical instabilities and leads to non-reliable estimates of the n and subsequent a values. Also, phase unwrapping is highly dependent on the dynamic range of the frequency spectra and is therefore band limited such that one needs to arbitrarily weigh both the phase and amplitude while solving the problem in the frequency domain. Most importantly, phase unwrapping is intrinsically error-prone in the tumor regions where the raw THz-TDS signals are low since the transmitted THz signals get highly attenuated while traversing through lossy regions.
The present disclosure provides a novel, time-domain technique to extract n and α imaging markers directly from the raw THz-TDS signals. This method contains a maximum a posteriori probability (MAP) estimation of the imaging markers without resorting to a frequency-domain transformation of the THz pulses, and it does not involve any phase unwrapping procedure, making it robust to the phase unwrapping instabilities. Furthermore, the MAP method directly acquires high signal-to-noise ratio experimental signals for both the sample-under-test and the reference with femtosecond time resolution and very low noise. The latter allows one to obtain very accurate measurements of n and α within the analysis area, most notably tumor regions. In the MAP procedure, the reference pulse from an empty setup is passed through a filter that parametrically models the influence of wave propagation through the sample-under-test and produces a corresponding model sample pulse. In the next step, the filter parameters are optimized against the difference between the experimental sample pulse and modeled sample pulse as the objective function to obtain the imaging markers. This model also compensates for spurious multiple reflecting waves, as well as additive noise arising from both the detection electronics and laser power fluctuations used in the THz-TDS measurements. This gives us a straightforward way of noise-modeling, which is not possible using the aforementioned conventional frequency-domain analysis. The THz range n and α imaging markers extracted from the MAP procedure show a statistically significant distinction between various tumor tissue regions and their non-malignant equivalents. The coefficient of the refractive index variation extracted by MAP is at least one order of magnitude lower, as compared to that extracted from frequency-domain analysis. Hence, this technique gives a more robust and conservative extraction of the imaging markers, especially for detection within optically lossy tumor regions.
For a fuller understanding of the nature and objects of the disclosure, reference should be made to the following detailed description taken in conjunction with the accompanying drawings.
Pancreatic ductal adenocarcinoma (PDAC) is an aggressively progressive malignancy that contributes to the third-highest number of cancer deaths in the United States. The total five-year survival rate is 9% due to the absence of timely diagnosis and inadequate response to conventional treatment procedures such as surgery, chemotherapy, and radiation therapy. More than 80% of PDAC patients are diagnosed with the advanced stage of the disease often after metastasis and, at the time of diagnosis, there are no curative treatments. The currently available serum biomarkers, like CA19-9, are insufficient to detect pancreatic cancer at an early stage due to their low specificity and sensitivity. At diagnosis, merely 20% of the patients qualify for a potentially curative pancreatectomy, and most patients, nevertheless, experience lethal recurrence and/or systemic metastases regardless of second-line intervention.
The existing standard chemotherapy with “gemcitabine” has very narrow efficiency, extending the patient's overall survival by only 6-12 weeks. This poor performance of current standard treatments is often associated with the lack of understanding of the disease's complex biology, especially its heterogeneous microenvironment. Alternatively, immunotherapy approaches that often employ immune-priming neoadjuvants, such as stereotactic body radiotherapy (SBRT), aim to stimulate immunogenic tumor cell death and thereby educate and amplify the antitumor immune response. However, tumor cells are capable of mitigating DNA damage to escape cell death mechanisms, leading to both interpatient and intratumoral response variabilities. The present disclosure provides terahertz (THz) imaging techniques useful for mapping and measuring the cytotoxic responsivity of PDAC to neoadjuvant therapies, such as SBRT. Hence, probing the treated PDAC microenvironment using THz imaging can help to investigate whether a tumor is responding to or likely to respond to a given therapy. This information can then be used to assess the efficacy of neoadjuvant or first-line therapy and subsequently inform adjuvant and/or second-line treatment approaches. Currently, comprehensive tumor characterization requires multiplexed immunohistochemistry assays that are expensive and time-consuming given the large number of molecular targets needed to identify and validate each tumor property. Instead, THz time-domain spectroscopy (THz-TDS) based imaging can be performed to acquire the same level of information at a fraction of the cost.
According to the literature reviewed above, there is a crucial demand to develop new technologies with a novel imaging marker competent for probing and identifying the complex tumor microenvironment. Hence, THz time-domain spectroscopy (THz-TDS) can be applied to probe the heterogeneity in the PDAC microenvironment. The THz-TDS technique is a label-free, noninvasive, and nonionizing tool for biomedical imaging, especially in tumor prognosis. THz radiation lacks the energy to break chemical bonds or ionize molecules/atoms in studied tissues, making it harmless to living organisms, in contrast to much higher energy photons such as ultraviolet light or, especially, X rays. THz-TDS provides submillimeter spatial resolution and molecular fingerprinting by providing both the frequency and time-domain information and could be capable of detecting pancreatic cancers.
Extensive bioimaging research based on the THz-TDS technique has been conducted on various types of malignancy, both in vitro and ex vivo, with reports revealing significant differences in the tissue properties in tumors as compared to their healthy controls (referred in the literature to as a normal tissue). However, despite the availability of vast and rich literature, all these studies lack standardized THz imaging markers to map out the tissue properties. Presently, there are mainly two approaches to report the difference between the tumor and normal tissues: the first is to map an image of time-or frequency-domain signal amplitudes measured at corresponding locations, i.e., the maximum amplitude of the signal from the tumor sample, normalized with respect to a reference (either an empty setup or a healthy control) and the second is reporting a difference in the tissue's optical parameters like the refractive index n and/or the absorption coefficient α in the THz frequency region.
The present disclosure provides an optimized set of imaging markers extracted by
a technique based on maximum a posteriori probability (MAP) estimation from pulsed THZ time-domain data for murine tissue with PDAC. The differences in optical parameters in the THZ region between different areas within the tissue could be attributed to heterogeneity in the tissue constituents. THz spectroscopy has demonstrated detectable contrasts in many freshly harvested biological tissues that can be attributed to differences in water content. Conversely, examples described in the present disclosure demonstrate the formalin-fixed paraffin-embedded (FFPE) tissues interrogated in the absence of water also show detectable THz contrast. We hypothesize that the presence of collagen and its variational density are major contributors to the observed contrasts in the microenvironments of FFPE PDAC tissues.
Since optical parameters can be the crucial markers for image reconstruction and understanding light-tissue interactions, accurately measuring them is necessary to provide reliable optical images at the THz range and their biophysical interpretation. In addition, the differences in imaging markers between normal and malignant tissues can be used to make a clinical diagnosis. Hence, efficient THz imaging markers capable of probing the tissue microenvironment can not only shed new light on the tumor prognosis but also can help in its treatment planning. In this present disclosure, PDAC is used as a non-limiting case study, but the presented approach could be used for any tumor characterized using a THz-TDS technique. In this disclosure, we report the first experimental evidence of THz-TDS probing PDAC tissues using time-resolved MAP estimation to reconstruct THz optical parameters. We refer to the THz refractive index and absorption coefficient as imaging markers that can delineate tissue heterogeneity within the PDAC microenvironment.
With reference to
embodied as a method 100 for extracting one or more imaging markers (i.e., refractive index (n), absorption coefficient (α), or both) of a THz-TDS scan (i.e., of a sample). The method 100 includes obtaining 103 an image (e.g., a 2D image) of a sample using pulsed terahertz time-domain spectroscopy. The one or more imaging markers are determined 106 using a maximum a posteriori probability (MAP) estimation applied to the obtained image. For example, the one or more imaging markers may be determined 106 by minimizing an error between the obtained image (Esam) and a modeled image (Esam.model) in the time domain. The modeled image may be produced by passing a reference pulse (Eref) through a filter that parametrically models the influence of wave propagation through the sample. In some embodiments, the filter may be a Fresnel function for a single dielectric layer in transmission geometry. For example, the filter may have a filter function (Kθ) provided by
where β is the amplitude scaling factor treated as Gaussian distribution of white noise, ω is angular frequency, d is sample thickness, and c is the speed of light (see further description below regarding Equation 3). Other filters may be used.
The error may be minimized using various techniques. For example, the error may be minimized according to {circumflex over (θ)}(n,α)=∥Esam−F−1{Kθ·F{Eref}}∥2, where F is a fast Fourier transform (FFT) operator (see further description below regarding Equation 4). In some embodiments, the error is a mean-squared error. In some embodiments, the error is minimized using maximum likelihood estimation.
The imaging markers may be determined over the image area (i.e., for various points across the image area). In some embodiments, the method 100 further includes generating 109 an image map based on the one or more imaging markers—e.g., an image map based on the refractive index, an image map based on the absorption coefficient, or both image maps, which may be embodied in separate image maps or a consolidated image map having values for both refractive index and absorption coefficient.
With reference to
The system 10 includes an emitter 30 configured to emit a THz reference pulse (Eref). The emitter may be any THz emitter useful for THz TDS, such as, for example, a photoconductive antenna (e.g., a low-temperature-Gallium Arsenide (LT-GaAs) emitter, etc.), an electro-optic (EO) crystal, etc. The emitter is configured to receive the pump beam and to emit the THz reference pulse.
The system includes a detector 40 configured to receive the probe beam and to measure a THz sample pulse after the THz reference pulse interacts with the sample 90. For example, in some embodiments, such as that depicted in
A processor 50 is in electronic communication with the detector 40. The processor 50 is configured to obtain a measured sample pulse (i.e., a measurement of the sample pulse—a signal representing the measured sample pulse). The processor may also receive a measured reference pulse (i.e., a measurement of the reference pulse, for example, without a sample—a signal representing the measured reference pulse). The processor is configured to determine one or more imaging markers (a refractive index (n), absorption coefficient (α), or both). The one or more imaging markers may be determined by minimizing an error (e.g., mean-squared error, etc.) between the obtained (measured) sample pulse and a modeled sample pulse (Esam.model) in the time domain. The modeled sample pulse may be produced by passing the obtained (measured) reference pulse through a filter that parametrically models the influence of wave propagation through the sample. The filter may be a Fresnel function for a single dielectric layer in transmission geometry, such as, for example, the filter of eq. 3. Other filters may be used as further described below. Minimizing the error may be performed by maximum likelihood estimation.
In some embodiments, the system 10 further includes a stage 12 for moving the sample. For example, the system may include an automated translational stage system. The stage may be configured to move the sample along two dimensions—e.g., an x—y stage. The processor may be configured to obtain additional sample pulses at different locations of the sample, and to repeat the step of determining one or more imaging markers for each additional sample pulse. In this way, the system may be configured to provide results over the image area—e.g., 2D results. Order of operations may be such that an entire THz TDS scan is performed before the one or more imaging markers are determined or the one or more imaging markers may be determined during the acquisition of the THz TDS scan (e.g., for each sample point or otherwise). A distance between each sample location may be predetermined according to the application. For example, a step size may be in the range from 10 μm to 500 μm inclusive.
In some embodiments, the system is further configured to generate an image map based on the refractive index of each sample pulse location, an image map based on the absorption coefficient of each sample pulse location, or both image maps, which may be embodied in separate image maps or a consolidated image map having values for both refractive index and absorption coefficient.
The term processor is intended to be interpreted broadly. For example, in some embodiments, the processor includes one or more modules and/or components. Each module/component executed by the processor can be any combination of hardware-based module/component (e.g., graphics processing unit (GPU), a field-programmable gate array (FPGA), an application-specific integrated circuit (ASIC), a digital signal processor (DSP)), software-based module (e.g., a module of computer code stored in the memory and/or in the database, and/or executed at the processor), and/or a combination of hardware-and software-based modules. Each module/component executed by the processor is capable of performing one or more specific functions/operations as described herein. In some instances, the modules/components included and executed in the processor can be, for example, a process, application, virtual machine, and/or some other hardware or software module/component. The processor can be any suitable processor configured to run and/or execute those modules/components. The processor can be any suitable processing device configured to run and/or execute a set of instructions or code. For example, the processor can be a general-purpose processor, a central processing unit (CPU), an accelerated processing unit (APU), a field-programmable gate array (FPGA), an application-specific integrated circuit (ASIC), a digital signal processor (DSP), graphics processing unit (GPU), microprocessor, controller, microcontroller, and/or the like.
The following discussion provides non-limiting examples based on experiments conducted using systems and methods according to the present disclosure. The methods, systems, and materials used are solely to illustrate such example embodiments.
Frequency-Domain (FD) Parameter Estimation Technique.
An advantage of the THz-TDS method is that it can probe the sample's contribution to both the amplitude and phase of the THz radiation, which makes it possible to evaluate the sample's optical parameters without employing Kramers-Kronig relations. This is, however, a double-edged sword when it comes to extraction of the optical parameters. The standard FD approach is to take a Fourier transform of both the sample and reference pulses and use the sample spectrum normalized to the reference one to obtain the complex transmission or reflection coefficients based on the geometry of the experimental setup and, next, use it in the following equation:
where Eref and Esam are the Fourier transforms of the reference and the sample TD signals, respectively.
In our case of a thick sample the extinction coefficient <<1, so ignoring the Fabry-Perot terms, the complex transfer function can be written as the following approximated form using the Fresnel equation:
d stands for the sample thickness, c is the speed of light, and ω is the angular frequency. Hence, from eq. 2, the inverse problem can be solved, where both Esam (ω) and Eref (ω) are known quantities from the experiment and solving for n and Δ. This problem is traditionally answered analytically, assuming optically thick samples (nd>1.5 mm) and ignoring the phase term in the transmission coefficient and the losses during the pulse propagation. In this approach, one evaluates the real part of n by unwrapping the phase of {tilde over (t)}, which often introduces numerical instability.
Another approach taken in the literature is to solve this inverse problem iteratively by calculating n using the unwrapped phase and including an imaginary term to offset the loss difference. To do so, for each frequency, an error function with arbitrary weighting that contains both the modulus and phase error between the experimentally obtained and modeled transmission coefficients is minimized. Nonetheless, causality is not satisfied in this calculation, which ends up taking the shape of the Kramers-Kronig relation in the problem. This poses a substantial issue during the phase unwrapping because this is highly dependent on the dynamic range and, thus, is band limited. The latter is the principal draw back of the FD parameter extraction method, requiring further steps in phase unwrapping, since the phase gets lost beyond the dynamic range. The FD method is also limited by the arbitrary weighting of the phase and the amplitude in the error function. In literature, it has been reported that the signals transmitted through the cancer tissue regions appear to be highly attenuated, posing a substantial challenge in phase unwrapping.
To overcome the shortcomings of the FD parameter extraction approach. embodiments of the present disclosure may solve the inverse problem with full TD inversion. We consider the reference and the sample pulses, measured by THz-TDS, as a dynamical system. Hence, we adopt a transfer-function-based approach to extract the optical parameters.
There are several advantages of solving the inverse problem in the TD with respect to FD. In TD, we can acquire high-signal-to-noise (SNR) experimental signals for both the sample and the reference with femtosecond time resolution and very low noise, which helps us have more accurate estimates of the tissue n and α parameters. Therefore, we describe the estimation problem as the root-mean-square difference of the experimental sample signal and the modeled sample trace from the reference. Thus, we project this as a MAP estimation problem. Similar time-domain minimization strategies for inverse problems in medical imaging have been demonstrated in ultrasound elasticity imaging to provide reliable estimates in ultrasound-based rheological parameter inversion.
In order to express the MAP estimator for the pulsed THz-TDS experiment, we traverse the reference pulse Eref through a filter Kθ, which parametrically simulates the effect of the THz propagation through a sample to generate a modeled sample pulse. Then, using the difference between the experimental sample pulse Esam and the modeled sample pulse as an objective function, we optimize the filter parameters. We treat Kθ as a continuous function for the sake of convenience. In the present model, Kθ=Γ(n*(θm), Eref, Esam), where n*(θm) is the complex n, while θm denotes a subset of parameters that describe the system and is regulated by the type of the model applied. Thus, the exact expression of the filter function depends on the dielectric model under consideration. For simplicity, we chose a Fresnel equation for a single dielectric layer in transmission geometry, so for a thick sample, Kθ takes the following form:
where β is the amplitude scaling factor treated as Gaussian distribution of white noise, which is incorporated to compensate for variations in the reference pulse and the incident laser train amplitude fluctuations. We note that the pump beam power and low-frequency amplitude fluctuations are the major sources of noise in the THz-TDS system, and using the TD approach we can perform the noise modeling in a much simpler way, which is not possible in the FD analysis. The other benefit of the MAP method is that the filter function Kθ is modular in a sense that the system identification approach can be extended to include Fabry-Perot reflections and complex geometry conditions. For simplicity, in the present study, we use the Fresnel transfer function without the Fabry-Perot effect, but the same routine could be adapted for measurements in a reflection geometry, or studying multilayer samples, by simply changing the transfer function, or by adding the higher order Fabry-Perot terms. A general form of filter in transmission geometry, without any approximation, may be given by:
A general form of filter in reflection geometry, without any approximation, may be given by:
The next step is the maximum likelihood estimation (MLE) process to best estimate the parameter values that transform Eref and Esam, assuming uniform priors of n and α over the reconstructed parameters. It is noted that the amplitude scaling factor β was not an a priori known parameter but instead a posteriori derived. We then solve for the posterior probability of these parameters by using the time-domain minimization. For a particular point scan, knowing Eref and d, we can construct the estimation problem in TD as the sum of mean-squared errors (MSEs) of the experimental trace and the modeled trace, shown as:
The right-hand term of eq. 4 is the difference between an experimental Esam(t) pulse and the Esam.model (t) one, reconstructed in TD from Eref. We first transform Eref(t) to its frequency-equivalent Êref(ω) using a temporal FFT operator F and multiply it by the impulse-function, which in our case is the Fresnel operator Kθ(ω) defined in eq 3. Next, we transform the KθÊref(ω) product back to TD using the inverse F−1 operator and, finally, compute the l2 norm of the residual. MLE yields estimations of the Fresnel parameters θn,α, so the problem reduces to a two-parameter model and these parameters driving the impulse transform are the optical parameters of interest, namely, n and α [θm→θm(n, α)]. A block diagram of the MAP algorithm is presented in
The MLE reconstruction of a pulse transmitted through our tissue sample is mathematically implemented using a nonlinear least-squares routine in MATLAB (R2021a). In this work, we select a simple gradient-free Nelder-Mead optimization algorithm because of its robustness and easy convergence. This method calculates a new error function (the l2 norm) at each iteration based on the current values of the parameters of interest and allows solving the problem for determining a parameter update by completing each iteration. This method gives LI-regularized estimates that can effectively deal with zeroes or large numbers in the solving equation. Since most optimization routines are sensitive to the prior values in order to achieve the global minima, we select initial parameters that are close to the globally optimized parameters. For this, we use the prior values of n and α calculated from the regular FD analysis at their center frequency. After the optimization is completed, we register the optimized values of n and α, which are the average values within the usable frequency range and use them as markers for differentiation of the studied sample characteristics to ensure reproducibility of findings and subsequent biological significance.
We made two cross-sectional scans on a 4 mm thick paraffin embedded PDAC tissue with the 100 μm step size in both transverse (x) and longitudinal (y) directions [see also
Two-Dimensional Raster Scans. Panels a and b in
For completeness of our work, we calculated and present here a comparison between the imaging markers obtained using MAP and FD techniques for paraffin-embedded normal and PDAC regions in a form of boxplot representation, as shown in
Table 1 (
Table 1(a) (
Table 1(b) (
In conclusion, we established a set of imaging markers, n and α, by performing the MAP estimation process on experimental THz transients collected using the THz-TDS technique. We have demonstrated that this MAP-based THz parameter extraction pipeline can effectively return THz-regime parameters of the tissue by only knowing TD THz traces that uniquely map characteristics of the sample-under-investigation. We validated the effectiveness of our algorithm by performing cross-sectional line scans of PDAC as well as normal tissue samples encapsulated in paraffin. We extrapolated our method to achieve 2D raster scans of a pancreatic tissue sample with different anatomical regions to show that even subtle changes in the tissue microenvironment markedly impacted the tissue optical properties in the THz range. We can map those changes using the markers extracted from the MAP. Thus, our work intends to establish standardized imaging markers for THz imaging of PDAC tissue to enable a reproducible and unbiased analysis of THz-TDS measurements. Our mathematical approach should be valid for any tissue samples studied using the transient THz spectroscopy method. This work demonstrates applicability of the THz-TDS imaging method for examination of subregions of a complex tumor case such as pancreatic ductal of adenocarcinoma and shows the potential of THz imaging as an ex vivo imaging platform for objectively mapping tumor responses. One potential limitation of this work is that we need to select initial parameters close to the global optimized parameters to achieve global minima. Another limitation is that we have to evaluate the parameters for each pixel from a TD trace taken for that pixel, making the entire evaluation and image mapping computationally heavy and time consuming. We intend to address these issues in our future work by employing more cost-and time-efficient methods, by, e.g., parallelizing our code.
In the experimental embodiment, the THz line-scans and THz maps were generated by manually moving the x-y stage and, subsequently, saving the signal information at each pixel location. Some embodiments may use an automated translational stage system with reduced scan step size to improve the spatial resolution as well as increase the data acquisition speed. This will enable the production of high-resolution, large-area THz images that can be used to identify tissue sub-regions with clearly defined borders between them. Embodiments of the present disclosure may be used for THz path modeling through pancreatic tissue with complex heterogeneity to probe the tumor microenvironment's subtleties by understanding the nature of THz interaction with the tissue. Embodiments of the present disclosure may advantageously use substrate tissue matching, as the substrate may play a role in the reconstruction of the THz imaging markers of the tissues. In conclusion, our experiments were conducted utilizing a commercial large-footprint Ti: sapphire laser on an optical table. Other femtosecond fiber lasers may be used, some of which are more compact. Utilizing these lasers, the entire THz-TDS system has the potential to be designed as a compact, portable unit.
Embodiments of the present disclosure may be used to improve diagnosis, evaluate the effectiveness of a treatment (e.g., SBRT, chemotherapy, etc.), or in other ways. For example, the present techniques may be used to look for areas of DNA damage. In another example, the present techniques may be used to evaluate skin hydration. In another example, the present techniques may be used to evaluate tissue viability, for example, in burn victims.
It is noted that index of refraction is related to permittivity, so an imaging marker may be described in terms of dielectric function (complex permittivity) as an equivalent of refractive index. As such, the use of the term refractive index is intended to include the use of dielectric function.
Although the present disclosure has been described with respect to one or more particular embodiments, it will be understood that other embodiments of the present disclosure may be made without departing from the spirit and scope of the present disclosure.
This application claims priority to U.S. Provisional Application No. 63/579,024, filed on Aug. 27, 2023, now pending, the disclosure of which is incorporated herein by reference.
Number | Date | Country | |
---|---|---|---|
63579024 | Aug 2023 | US |